机构投资者对DexCom持有不同的兴趣,尽管有“灵活购买”评级,但买卖活动混合进行。 Institutional investors show divided interest in DexCom, with mixed buying and selling activities despite a "Moderate Buy" rating.

机构投资者对DexCom公司的兴趣好坏参半,DF Dent & Co.公司的股份增加了15.6%,而Cynosure Group LLC的股份减少了89.8%。 Institutional investors show mixed interest in DexCom, Inc., with DF Dent & Co. Inc. increasing its stake by 15.6% while Cynosure Group LLC reduced its holdings by 89.8%. DexCom是一家医疗设备公司,设计和销售连续的葡萄糖监测系统,如Dexcom G6和G7用于糖尿病管理。 DexCom, a medical device company, designs and sells continuous glucose monitoring systems like the Dexcom G6 and G7 for diabetes management. 尽管分析师对第四季度收入的预期略微缺失,但DexCom的共识评级是“机动购买”,目标价格为99.82美元,反映了投资者持续的兴趣。 Despite slightly missing analysts' fourth-quarter earnings expectations, DexCom has a "Moderate Buy" consensus rating and a target price of $99.82, reflecting ongoing investor interest.